The advance could be especially important for men receiving radiopharmaceutical therapy for advanced prostate cancer. The treatment received U.S. Food and Drug Administration approval in 2022 and uses a radioactive drug linked to a molecule that seeks out prostate-specific membrane antigen, or PSMA, found on many prostate cancer cells. The resulting therapy, based on the radioisotope lutetium-177, or 177Lu, travels through the bloodstream and deposits radiation in tumors throughout the body. Unlike external-beam radiation, which targets a defined region from outside the body, RPT can reach cancer that has spread to multiple locations.

Its systemic reach is also the source of one of its central dangers. The radioactive compound can accumulate in healthy tissues, including the kidneys and liver. The same radiation that damages cancer cells can injure normal organs when exposure becomes too high. “The main issue with many cancer treatments is toxicity,” says Joyita Dutta, a professor in the Riccio College of Engineering at UMass Amherst and senior researcher on the project. “Whether it’s radiation, chemo, or radiopharmaceutical therapy—whatever mechanism kills the cancer cells also hurts healthy tissue.”

Doctors can estimate this risk through dosimetry, the process of determining how much radiation has been absorbed by specific tissues. After treatment, medical scans show where the radiopharmaceutical has concentrated, but images alone do not directly reveal the absorbed dose. Dosimetry requires additional computational analysis that combines information about the radioactive material’s distribution, its physical decay and the way emitted particles travel through tissue. The most accurate existing calculations can take hours for a single patient, limiting their usefulness in routine clinical decision-making.

DiffuDose was designed to make that analysis fast enough to support treatment planning. The system combines two artificial intelligence modules. The first produces a coarse estimate of the radiation distribution, rapidly identifying the broad pattern of dose across the body. A second module then refines that estimate, reconstructing a full-resolution map that captures finer variations from one region to the next. The approach uses diffusion-guided deep learning, a class of generative modeling techniques that can progressively refine an initial prediction toward a more detailed and realistic result.

The output is not simply a single number describing a patient’s total radiation exposure. It is a three-dimensional, pixel-by-pixel representation of how the dose is distributed throughout the body. Such a map can show whether a tumor is receiving substantial radiation while nearby organs remain below a potentially dangerous threshold. That distinction is essential because two patients given the same administered activity may absorb very different amounts of radiation depending on anatomy, blood flow, tumor burden, kidney function and the way the radiopharmaceutical is cleared.

In testing, the UMass Amherst team compared DiffuDose with six other computational approaches. The new model delivered the strongest overall quantitative performance and maintained consistently high accuracy across several organs, including both kidneys and the liver—organs that are particularly important when assessing toxicity in 177Lu-PSMA therapy. Most notably, it generated results matching the accuracy of the gold-standard method in under 23 seconds per patient, a dramatic reduction from the hours required by conventional calculations.

Rapid dosimetry could eventually give oncologists more flexibility in deciding how much treatment a patient can safely receive and when another cycle should be administered. If a patient’s organs tolerate an initial treatment well, a subsequent dose might be adjusted upward; if radiation accumulates in a vulnerable organ, treatment could instead be reduced, delayed or reconsidered. The system is not intended to replace clinical judgment, and its performance will need to be validated in broader patient populations and prospective clinical studies before it can guide routine care. Its immediate significance is that it demonstrates how computational methods might remove a major practical barrier to individualized RPT.

Dutta’s group is now pursuing collaborations with UMass Chan Medical School to develop models that combine post-treatment imaging with biological information, including blood biomarkers. The goal is to determine not only where radiation is deposited, but also how a patient’s disease is responding. The project involved collaborators Michael King at UMass Chan Medical School, Alejandro Bertolet and Quanzheng Li at Massachusetts General Hospital, and Babak Saboury at the Institute of Nuclear Medicine in Bethesda, Maryland. The findings were reported in IEEE Transactions on Radiation and Plasma Medical Sciences under the title “DiffuDose: A Diffusion-Guided Model for Personalized Dosimetry for 177Lu-PSMA Radiopharmaceutical Therapy for Prostate Cancer.” If further validated, the technology could help transform RPT from a largely standardized treatment into a more responsive therapy calibrated to each patient’s unique radiation biology.

Subject of Research: People

Article Title: DiffuDose: A Diffusion-Guided Model for Personalized Dosimetry for 177Lu-PSMA Radiopharmaceutical Therapy for Prostate Cancer

News Publication Date: 22-Jun-2026

Web References: University of Massachusetts Amherst; IEEE Xplore: https://ieeexplore.ieee.org/document/11573134

References: IEEE Transactions on Radiation and Plasma Medical Sciences. DOI: 10.1109/TRPMS.2026.3705613

Keywords: Radiopharmaceutical therapy, prostate cancer, 177Lu-PSMA, personalized dosimetry, artificial intelligence, deep learning, diffusion models, radiation dose mapping, medical imaging, cancer treatment, precision medicine, radiation toxicity

Radiopharmaceutical therapies represent a paradigm shift from traditional external-beam radiation or brachytherapy by delivering radionuclides systemically. These radioisotopes conjugated to ligands navigate the circulatory system to bind selectively to tumor biomarkers, such as prostate-specific membrane antigen (PSMA) in prostate cancer. Upon binding, these agents emit targeted ionizing radiation that induces DNA damage specifically within cancer cells, thereby sparing surrounding healthy tissues. The mechanistic elegance of RPT resides in this molecular targeting, affording improved therapeutic indices and a compelling safety profile.

Despite the intricate biochemistry involved, the expansion of RPT remains deliberate yet persistent. Only two radiopharmaceutical agents have secured FDA approval in the past decade, with Lu-177 PSMA-617 as the trailblazer for metastatic castration-resistant prostate cancer (mCRPC). Nonetheless, a burgeoning pipeline of next-generation radioisotopes and ligands under clinical evaluation promises to extend applicability to hematologic, gastrointestinal, and other prevalent malignancies. This rich investigational landscape was prominently showcased in the collected symposium abstracts, reflecting a vibrant research ecosystem attuned to evolving oncological demands.

One of the symposium’s pivotal contributions is a meta-analysis pooling data from seven randomized phase II and III trials involving over 2,500 mCRPC patients treated with Lu-177 PSMA-617. The analysis elucidated a statistically significant prolongation of progression-free survival compared with standard-of-care systemic therapies, which primarily include androgen receptor signaling inhibitors. Notably, this extended disease control did not incur a concomitant rise in grade 3 or higher toxicities, highlighting the therapy’s favorable tolerability. While overall survival differences remained statistically nonsignificant—likely influenced by crossover treatments in control groups—these findings robustly advocate for RPT’s integration earlier in prostate cancer management algorithms.

The biology underpinning PSMA-targeted radioligand therapy distinguishes it fundamentally from hormone-directed therapies. Rather than modulating androgen-driven tumor growth, Lu-177 PSMA-617 delivers beta-particle radiation selectively to cancerous cells, causing lethal double-stranded DNA breaks. This targeted cytotoxic mechanism potentially complements existing systemic therapies, sparking interest in multimodal regimens and combination trial designs aimed at optimizing patient outcomes. Emerging trials, such as the phase II LUNAR study, further explore these synergistic possibilities.

Concomitantly, national healthcare utilization data reveals an extraordinary uptick in RPT administration, with Medicare claims documenting a more than 20-fold increase from 2013 to 2023. This exponential growth transcends multiple medical specialties, including diagnostic and interventional radiology, nuclear medicine, radiation oncology, and medical oncology/hematology. Diagnostic and interventional radiologists currently administer the majority of these therapies, reflecting an evolving multidisciplinary engagement in RPT delivery. This trend underscores the need for cohesive clinical workflows, cross-specialty training, and collaborative care models to safely scale the integration of these complex treatments.

Setup and sustainability of high-quality RPT programs represent operational challenges addressed during the symposium. Presentations detailed evidence-based frameworks suitable for diverse clinical environments, ranging from community-based oncology practices to large academic health systems. Emphasis was placed on multidisciplinary collaboration encompassing nuclear medicine expertise, radiation oncology oversight, and robust safety protocols to ensure precise radiopharmaceutical handling and patient monitoring. Additionally, consensus guidelines and white papers recently promulgated by ASTRO provide comprehensive recommendations on quality assurance and radiation safety specific to RPT infrastructure.

The symposium also highlighted critical educational initiatives designed to expand the skilled oncology workforce proficient in administering and managing RPTs. ASTRO’s establishment of national training centers aims to credential more physicians rigorously trained in the unique facets of radiopharmaceutical administration, patient selection, dosimetry, and regulatory compliance. These efforts address the acute need for specialized expertise as RPT adoption accelerates, ensuring that expanding access will not compromise patient safety or treatment efficacy.

Keynote addresses from luminaries such as former FDA Commissioner Dr. Stephen M. Hahn, now leading Nucleus RadioPharma, and Dr. Johannes Czernin of UCLA highlighted the translational and regulatory complexities shaping the RPT landscape. Their discourse underscored the intersection of scientific innovation, regulatory oversight, and market dynamics that collectively govern the development and dissemination of these therapies. Panel discussions delved into cutting-edge radiopharmaceutical agents under investigation, radiation protection considerations, and the evolving clinical paradigm from early phase clinical trials to integration into standard oncology practice.

The potential of radiopharmaceutical therapy to revolutionize cancer care is grounded in its ability to target microscopic disease with precision that surpasses conventional systemic therapies. As research progresses, emerging agents exploiting novel targets and employing alpha-particle emitters offer tantalizing prospects for enhanced tumoricidal potency while further reducing collateral toxicity. The challenges ahead lie in harmonizing multidisciplinary collaboration, optimizing sequencing with other modalities, and navigating regulatory and reimbursement landscapes to broaden patient access.

In summary, the first Multidisciplinary Radiopharmaceutical Therapy Symposium crystallized the transformative promise of RPT within oncology. Clinical data decisively points to improved progression-free survival and manageable safety profiles in advanced prostate cancer, a model for expansion into other malignancies. Meanwhile, real-world utilization trends reveal rapid adoption requiring coordinated multidisciplinary efforts and enhanced training infrastructures. Together, these developments herald a momentous shift towards personalized, targeted oncologic interventions fueled by breakthroughs in molecular imaging and radiochemistry.

Subject of Research: Radiopharmaceutical therapy for cancer treatment, specifically Lu-177 PSMA-617 in metastatic castration-resistant prostate cancer

Article Title: Radiopharmaceutical Therapies Usher in a New Era of Precision Oncology: Insights from the Inaugural Multidisciplinary Radiopharmaceutical Therapy Symposium

News Publication Date: February 17, 2026

Web References:

• Symposium press kit: http://www.astro.org/RPTpress
• Meeting website: https://www.astro.org/meetings-and-education/micro-sites/2026/rpt-symposium
• LUNAR trial news release: https://www.astro.org/news-and-publications/news-and-media-center/news-releases/2025/radiopharmaceutical-added-to-stereotactic-radiation-delays-prostate-cancer-progression-in-patients-w
• ASTRO white paper on RPT safety and quality: https://www.practicalradonc.org/article/S1879-8500(25)00071-2/abstract
• ASTRO training centers launch: https://www.astro.org/news-and-publications/news-and-media-center/news-releases/2026/astro-launches-national-radiopharmaceutical-therapy-training-centers-to-strengthen-oncology-workforc

Keywords: Cancer treatments, Cancer medication, Drug therapy, Cancer research, Oncology, Radioisotopes, Prostate cancer